There were 62 males and 38 females; 68 % were adults. Morphology was consistent with ALL (43%), AML (42%) or inconclusive (15%). Immunophenotyping disclosed B+Myeloid (59%), T+Myeloid (35%), B+T (4%) or trilineage (2%) combinations.
Introduction
Biphenotypic acute leukemia (BAL) is a very rare disease possibly arising from a haemopoietic pluripotent stem cell (1) . The diagnostic criteria until now were based on the scoring system proposed by the European Group for the Immunological classification of Leukemias (EGIL) (2) that was adopted by the WHO 2001 classification (3) . Single case reports and limited data in small series of patients classified according to the EGIL criteria have been documented (4) (5) (6) (7) (8) (9) (10) (11) (12) . A significant number of other cases reported as BAL, did not fulfill the EGIL criteria and instead represented acute lymphoblastic (ALL) or myeloid leukaemias (AML) with aberrant antigen expression of differentiation antigens from another lineage. (13) (14) (15) (16) The most recent edition of the WHO classification has established and published new criteria for the diagnosis of BAL. It has also adopted a new designation for this disease, which is now termed mixed phenotype acute leukemia (MPAL) (1) . The previous criteria have been now refined to ensure that cases of "bona fide" ALL or AML with aberrant antigen expression, AMLs with recurrent chromosomal abnormalities or Chronic Myeloid Leukemia (CML) in blast crisis are excluded. Moreover, therapy-related myeloid neoplasms and AML with myelodysplasia-related features should be classified as such, even when they have an MPAL immunophenotype. Briefly, the WHO definition of MPAL is based on the expression of strictly specific T-lymphoid (cytoplasmic CD3) and myeloid {myeloperoxidase, (MPO)} antigens, the latter shown by either flow cytometry (FCM) or cytochemistry and/or clear evidence of monocytic differentiation.
Since there is no single antigen strictly specific for B-cells, B-cell lineage assignment in MPAL relies on the strong expression of CD19 together with another B-cell associated marker or, in cases with weak CD19, on the expression of at least three B-lineage markers (1) . In addition, the WHO recognizes two distinct categories: MPAL with the t(9;22)(q34;q11)/BCR-ABL1 and MPAL with t(v;11q23)/MLL rearrangement. The remaining cases are designated as MPAL NOS (not otherwise specified).
The rarity of MPAL and the lack of uniform diagnostic criteria applied in the cases so far reported have made it difficult to establish whether these leukemias have distinct characteristics and which is the best therapeutic approach for these patients. Thus, there is 
Material and Methods

Case selection
This study included 100 patients diagnosed with mixed phenotype acute leukemia (MPAL) according to the recent WHO criteria (1). They were selected from the archives of acute leukemias over a 15 year period and the majority of patients presented over the last 5 years. Most cases were from England (64), Austria (21) and Holland (8) and a minority from France (3), Sweden (2), Spain (1) and Czech Republic (1) . Among the acute leukemias, the frequency of MPAL in the participating centers was 0.5-1%. Cases were classified as ALL or AML by morphology and cytochemistry for MPO, Sudan black B (SBB) and non-specific esterases according to the French-American-British (FAB) criteria (17) . Cytogenetic analysis was carried out in 76 cases and fluorescence in situ hybridization (FISH) and/or molecular analysis to detect BCR-ABL1, ETV6-RUNX1
and MLL rearrangements in 14, 8 and 7 cases respectively. Cases with acute promyelocytic leukemia, those with AML with recurrent chromosome translocations, i.e. t(8;21) or inv (16) , CML in blast crisis, AML following myelodysplasia and cases fulfilling the EGIL criteria but being MPO negative were excluded.
Flow cytometry immunophenotyping
FCM immunophenotyping was performed on either isolated bone marrow (BM) mononuclear cells or in whole BM specimens following lysis according to standard techniques. Prior to 2000, the blast population was identified by a forward scatter (FSC) and side scatter (SSC) gate and thereafter on CD45 int/low blast cells versus SSC.
According to each center´s protocols, multiparameter immunostaining with fluorochrome directly labeled monoclonal antibodies (MoAbs) was performed. Surface antigen expression was considered positive if at least 20% of blasts showed a positive labeling
For personal use only. on April 2, 2017. by guest www.bloodjournal.org From 6 (2). For cytoplasmic antigen expression, the threshold was 10%. If findings by FCM were equivocal, confirmation of the staining by immunocytochemistry was carried out. The specificity of MPO staining was validated by cytochemistry and false positives due to autofluorescence were ruled out. The core of MoAbs investigated comprised: cytCD3, CD2 and CD7 for the T-cell lineage, anti-MPO, CD13 and CD33 and CD117 for the myeloid lineage and CD19, CD10, cytCD22 and/or cytCD79a for the B-lymphoid lineage. The majority of cases were also investigated for the expression of nuclear TdT, CD34 and HLA-DR and a substantial proportion for CD14, anti-lysozyme, CD15, CD65 and cytoplasmic μ chain.
Cytogenetics
Conventional karyotypic studies were carried out on BM cells after 24-48 hours culture in tissue culture medium according to standard techniques. A complex karyotype was defined when three or more clonal structural chromosomal abnormalities were present.
FISH analysis for the BCR-ABL1, ETV6-RUNX1 and MLL rearrangements was carried out using commercial probes according to manufacturer's instructions and following standard techniques.
Statistics
The chi-squared and Fisher exact tests were used for the analysis of clinical and laboratory variables. Survival curves were calculated by the Kaplan Meier method and differences between groups were assessed by means of the log-rank test.
Results
Patients
There were 62 males and 38 females (M/F: 1.6). Twenty eight (28%) patients were children, 2 of whom were infants (< 1year old) and 68 (68%) were adults (>15 years old); the age of 4 patients was not available. There was no selection for treatment. In each country, patients were treated according to national protocols for ALL or AML and these included the same drugs and similar regimens. Complete remission (CR) was considered by standard morphology and recovery of the blood counts. 
Flow cytometry immunophenotyping
Immunophenotyping showed that 59 cases (59%) had a B-lymphoid plus myeloid immunophenotype (B+My), 35 (35%) a T-lymphoid plus myeloid immunophenotype (T+My), 4 (4%) a B plus T lymphoid immunophenotype (B+T) and in the remaining 2 cases (2%) there was evidence of trilineage concomitant expression (myeloid, B and T lymphoid) (My+B+T) ( Table 1 ). There were no significant differences between B+My and T+My immunophenotypes for age (p=0.2), sex (p=0.7) and morphology (p=0.2).
However, 3 out of the 4 patients with the B+T immunophenotype were children and the two cases with trilineage differentiation were adults. All 4 patients with a B+T immunophenotype and the 2 with a My+B+T immunophenotype had an ALL morphology.
TdT was positive (>10% blasts) in 81/91 (89%) cases. The 10 TdT-negative cases corresponded to 7 patients with a T+My immunophenotype, 2 with a B+My immunophenotype and 1 with a B+T immunophenotype. The intensity of TdT staining in the MPAL was not different from that seen in ALL cases (data not shown). HLA-Dr was strongly positive in 62/67 (92%) and CD34 in 62/83 (74%) cases.
Results of other antigen expression are described below according to the myeloid and T and B lymphoid commitment.
Myeloid commitment in cases with B+My and T+My immunophenotype
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The McAb anti-MPO was expressed in at least 5% of blasts in 90 out of 94 cases (98%) and in more than 20% blasts in 69 cases (76%). Four cases were not tested by FCM but 5-9% of blasts were positive for MPO and SBB by standard cytochemistry. Therefore, there was evidence of myeloid commitment in all cases. There was a variable proportion of blasts (5-95%) coexpressing anti-MPO and lymphoid markers in all but the four patients in whom only MPO cytochemistry was available and double staining could not be performed.
In our cohort of patients, CD13 was positive in 70/94 (74%) and CD33 in 62/94 (66%).
All except 9 cases expressed MPO together with CD33 and/or CD13 (see scores below).
Expression of other myelo-/monocyte-associated markers was as follows: CD14 in 4/48 (8%), CD15 in 6/52 (12%), lysozyme in 13/42 (31%) and CD117 in 34/65 (52 %) cases. (1/2) and weak CD79a in the single case tested. (Figure 3) CD19 was strongly positive in more than 20% of the blasts from 54/59 (93%) cases and the proportion of positive blasts was greater than 50% in 45 cases. In all of them the blasts were positive for CD10, cytCD22 and/or cytCD79a. In 5 cases, CD19 was weak or expressed in less than 20% of blasts, but the cells in two of them strongly expressed CD10 and cytCD22, in another two cases cytCD22 and cytCD79a were positive and the immunophenotype in the remaining case was cytCD22, cytCD79a and cytoplasmic μ chain positive. Expression of other lymphoid markers in this whole group was as 
T-lymphoid commitment in cases with a T+My immunophenotype
B-lymphoid commitment in cases with B+My immunophenotype
Cases with a B+T lymphoid immunophenotype and Trilineage differentiation (Figure 4)
Blasts in all 4 B+T lymphoid cases expressed CD19 strongly together with one or more B-lymphoid markers. A high proportion of blasts from 3 cases expressed cytCD3, all were CD2+ and 3/4 CD7+; in the remaining case, the proportion of cytCD3+ blasts was low but confirmed by immunocytochemistry and double immunostaining with TdT and cytCD3. TdT was positive in 3 cases and CD34 in one. All but one were adults and three had an abnormal karyotype (see cytogenetics). The majority of blasts in the 2 cases with trilineage differentiation were positive with four B-lymphoid markers, the three Tlymphoid markers and anti-MPO plus one or two myeloid markers. These two patients were adults with ALL morphology and one had a Ph+ chromosome with an additional iso(9)(q10)
EGIL scores
We analysed whether the MPAL cases included here according to the WHO could have been classified as BAL on the basis of the EGIL scoring system. All cases with B lymphoid commitment scored for this lineage 2.5 (8 cases) or greater and cases with Tlymphoid commitment had scores of 2.5 (6 cases) or greater. Regarding the myeloid commitment, all but 9 cases scored over 2. Cells from the 9 cases that scored only 2 had evidence of myeloid commitment by both immunostaining with anti-MPO and cytochemistry but were negative for other myeloid markers and/or not all the myeloidassociated markers were tested and therefore they would have not been classified as BAL according to the EGIL criteria
Cytogenetics
Out of the 76 patients in whom cytogenetic information was available, 15 (20%) had the t(9;22)(q34;q11) (Ph+) confirmed by FISH in 5 cases and with 4 of them having additional chromosomal abnormalities. Six (8%) cases had translocations involving the 11q23 breakpoint (MLL gene) of which three had t(4;11)(q21;q23), two
For personal use only. on April 2, 2017. by guest www.bloodjournal.org From t(11;19)(q23;p13) and one t(9;11)(p22;q23). In two of the latter cases the karyotype was complex with additional abnormalities. FISH analysis confirmed the presence of the fusion genes MLL-AF4 (2 cases) or MLL-AF9 (1 case) in all 3 of these cases investigated.
Twenty-four cases (32%) had a complex karyotype with three or more structural chromosome abnormalities, 21 (27%) had other abnormalities including two patients with a hyperdiploid karyotype and 10 (13%) a normal karyotype ( Table 2 ). The most commonly involved chromosomes in cases with a complex karyotype were: del(6)(q11-21) in 4 cases, structural or numerical abnormalities of chromosome 7 (7q-, -7 or t(2;7)) in 5 cases and del(5q) or -5 in 3 cases. Among the cases with other abnormalities, there were two patients with trisomy 4, two with a hyperdiploid karyotype and in two others FISH detected an ETV6-RUNX1 rearrangement that had been suspected by cytogenetics in one of them that had t(11;12;21)(p11;p13;q22). There was no evidence of BCL-ABL1
or MLL rearrangements in three cases investigated by FISH.
The relationships between karyotype and age, morphology and immunophenotype subtypes are shown in Table 2 . Although the presence of Ph+ was more frequent in adults with a B+Myeloid immunophenotype and MLL rearrangements were more often seen in children and patients with a B+Myeloid immunophenotype, the differences were not statistically significant (Ph+ versus other abnormalities p=0.2 and Ph+ versus phenotypes p=0.4). There was no significant correlation between age (p=0.3), sex (p=0.2), cell morphology (p=0.8), FAB subtype or immunophenotype (p=0.2) and the presence of a complex karyotype, other clonal abnormalities or a normal karyotype.
Response to therapy and outcome
Information on response to first line treatment was available for 67 patients; one infant (3 weeks old) did not receive treatment and died within a month. Out of the 67 patients, 27 received therapy for ALL, 34 were treated with AML schedules with the addition of imatinib in two, 5 had a combination of ALL and AML drugs and 1 patient received only imatinib. Twenty patients underwent autologous or allogeneic stem-cell transplantation.
Complete responses (CR) to ALL treatment were achieved in 23/27 (85%) but in three of these patients the responses were of short duration and an early relapse occurred; 4 patients did not respond. Fourteen out of the 34 patients (41%) treated with AML therapy Information on characteristic features of MPAL is very limited due to the rarity of these leukemias and to the new criteria established for its definition. Thus, a substantial number of publications refer to data on patients with miscellaneous diagnoses (12-16, 18, 19) and/or including true MPAL together with some cases that would not fulfill the present WHO criteria (4, 10, 11, 19, 20) . Blasts from all cases included in this study showed unequivocal evidence of myeloid and B-or T-lymphoid commitment as shown by the expression of lineage-specific antigens.
Only very rare cases showed involvement of the three lineages or of the two main lymphoid lineages. The two latter groups were very infrequent, accounting for a total of 6% of MPAL cases whilst the cases with a B+My immunophenotype accounted for over half and those with a T+My immunophenotype for over a third of the patients. This is in contrast to the recently reported pediatric series where a T+My immunophenotype was the most frequently found (11) . Only rare cases with trilineage differentiation have been previously described (4, 6, 11, 12) and a case with a B plus T lymphoid Our results also substantiate the robustness of the EGIL scoring system for the diagnosis of MPAL. Only a minority of cases included here would not have been classified as MPAL according to the EGIL scores. Conversely, we excluded here only 2 cases due to the presence of t(8;21), another with dysplasia and "secondary" AML and 11 cases because of the lack of MPO expression or monocytic differentiation (data not shown) We also observed a high incidence of cytogenetic abnormalities in MPAL with only 13% of the cases displaying a normal karyotype. However, no single cytogenetic abnormality was clearly over-represented indicating that MPAL does not result from a unique recurrent genetic abnormality. In this series, we could allocate 28% of cases into the two 5, 6, 7, 8, 10, 11 ). In our cohort of patients, the presence of the Ph chromosome or BCR-ABL1 rearrangement was less frequent than a complex karyotype. The Ph chromosome has been described in BAL (4, 5, 6, 7) but in our study it was not exclusively restricted to adults with a B+My immunophenotype as previously suggested, but also detected in a few patients with a T+My immunophenotype and/or children. Another abnormality involving the 11q23/MLL gene was detected in a small proportion of patients and it was preferentially, but not exclusively, found in children with a B+My immunophenotype. The t(4;11) is more often seen in ALL than in AML. A workshop on haematological malignancies with the t(4;11)(q21;q23) showed that 34% of these patients were infants and 95% of cases had ALL, 4.5% were AML with only one case having "biphenotypic" acute leukemia (28) . Although MLL rearrangements have been described in mixed lineage acute leukemias (11), most of the patients with this abnormality have a precursor B-ALL with aberrant expression of myeloid antigens, particularly CD15 and CD65 but not MPO (29, 30) . In addition, most of these cases have a pro-B/B-I-ALL or less frequently a pre-B/B-III immunophenotype (30) . In contrast to the t(4;11), the t(11;19)(q23;p13) translocation is more common in AML. However, it may also be seen in ALL when the breakpoint is at 19p13.3 and could be related to previous exposure to topoisomerase type II inhibitors T+My immunophenotype (9) . A recent study in pediatric cases classified according to the EGIL criteria has shown a relatively high incidence of EVT6/RUNX1 rearrangement in contrast to this series in which this abnormality was rarely present (2 cases). Although detailed immunophenotypic data were not given in the study by Gerr et al. (12) (4, 7, 10) and suggested that these are related to association with unfavorable markers such as pglycoprotein over-expression and unfavorable karyotype (4, 10) . However, these results need to be taken with caution due to the patients' heterogeneity and/or the small numbers included (4, 7, 10,) . The present study is neither a prospective nor a randomized study but the patients were treated with very similar and uniform protocols and two main prognostic markers in acute leukaemias such as age and cytogenetics were considered.
On this basis, our findings suggest that ALL-directed treatment seems more effective with a higher response rate and better outcome compared to an AML or to an AML+ALL schedule. A recent study focused on 33 MPAL pediatric patients has also shown a high CR rate for ALL (83%) compared to AML oriented (52%) therapy, and no differences in outcome when compared to a pediatric AML group but a poorer outcome compared to ALL (11) . Despite these findings, the authors suggested the use of AML based regimens as front line and if CR is not achieved a switch to ALL targeted treatment. Our data suggest that in the prognostic risk assessment two other variables might be considered as strong predictors for outcome: age and the presence of Ph chromosome. There is lack of expression of CD117. 
